Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515848 | 0.89 | CES2 (0.55) | MAPTL3MBTL1NR4A2SRD5A2CES2 | |
| SCHEMBL11633589 | 0.87 | MAPT (0.60) | MAPTL3MBTL1SRD5A2CES1NPC1 | |
| SCHEMBL4745782 | 0.85 | MAPT (0.50) | MAPTL3MBTL1NR4A2SRD5A2CES1 | |
| SCHEMBL27557474 | 0.85 | SLC1A1 (0.43) | MAPTL3MBTL1NR4A2SLC1A1CES2 | |
| SCHEMBL22733363 | 0.85 | NR4A2 (0.46) | MAPTL3MBTL1NR4A2SLC1A1SRD5A2 | |
| SCHEMBL6511713 | 0.85 | GSK3B (0.46) | MAPTL3MBTL1NR4A2SLC1A1SRD5A2 | |
| SCHEMBL8956315 | 0.85 | L3MBTL1 (0.65) | MAPTL3MBTL1NR4A2SRCNPC1 | |
| SCHEMBL3283011 | 0.83 | KCNK3 (0.51) | MAPTCES2CES1NPC1HPGD | |
| SCHEMBL29580879 | 0.83 | NPC1 (0.54) | MAPTL3MBTL1NR4A2CES2CES1 | |
| SCHEMBL9788780 | 0.83 | NPC1 (0.54) | MAPTL3MBTL1NR4A2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109836350-A | The environment-friendly preparation method of Atorvastatin key intermediate | 江苏暨明医药科技有限公司 | 2019-06-04 | — | — | CN | claimed |
| US-8815940-B2 | Coumarin-chalcones as anticancer agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-26 | — | — | US | claimed |
| US-20130210909-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-08-15 | — | — | US | claimed |
| EP-2601183-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | Council Of Scientific & Industrial Research (IN) | 2013-06-12 | — | — | EP | claimed |
| WO-2012017454-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-02-09 | — | — | WO | claimed |
| CN-115572244-B | 2' -Aryl chalcone compound, preparation method and application thereof in pharmacy | 复旦大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-115572244-A | 2' -aryl chalcone compound, preparation method and application thereof in pharmacy | 复旦大学 | 2023-01-06 | — | — | CN | disclosed |
| EP-3342767-B1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200392123-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200385357-A1 | SUBSTITUTED PYRIDAZINES AND 1,2,4-TRIAZINES AS PROSTACYCLIN RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10793529-B2 | Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10689372-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-7030240-B2 | 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| WO-2006034511-A1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | EPIX DELAWARE, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1622914-A2 | NEW PIPERIDINYLAMINO-THIENO 2,3-D PYRIMIDINE COMPOUNDS | Predix Pharmaceuticals Holdings, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | PGXHEALTH, LLC | 2005-10-06 | — | — | US | disclosed |
| US-20050222176-A1 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2005-10-06 | — | — | US | disclosed |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2004-12-09 | — | — | US | disclosed |
| WO-2004089312-A2 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-5532374-A | Method of preparation of bis-quinolines | HITACHI CHEMICAL COMPANY, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793529-B2 | Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators | PTGIR, PTGIS, TBXA2R | MAPT 3321/4885L3MBTL1 4825/4885NR4A2 1096/4885 |
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | HTR5A, HTR3A, HTR1A | MAPT 1950/4885L3MBTL1 4685/4885NR4A2 576/4885 |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | HTR5A, HTR2C, HTR1A | MAPT 3090/4885L3MBTL1 4774/4885NR4A2 875/4885 |
| US-10689372-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | PTGIR, PTGIS, PTGER1 | MAPT 2657/4885L3MBTL1 4819/4885NR4A2 2235/4885 |
| US-20200392123-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | MAPT 2657/4885L3MBTL1 4819/4885NR4A2 2235/4885 |
| US-20050222176-A1 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | HTR2B, HTR3B, HTR1B | MAPT 4403/4885L3MBTL1 4693/4885NR4A2 579/4885 |
| US-20200385357-A1 | SUBSTITUTED PYRIDAZINES AND 1,2,4-TRIAZINES AS PROSTACYCLIN RECEPTOR MODULATORS | PTGIR, PTGIS, TBXA2R | MAPT 3321/4885L3MBTL1 4825/4885NR4A2 1096/4885 |
| US-20130210909-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | HCCS, XPO5, CIAPIN1 | MAPT 3772/4885L3MBTL1 4296/4885NR4A2 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.